Data gathered: September 17
Alternative Data for Soligenix
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Google Trends | 57 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | 337 | Sign up | Sign up | Sign up |
| Instagram Followers | 225 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 12 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 12,675 | Sign up | Sign up | Sign up |
| Twitter Followers | 923 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| Youtube Subscribers | 815 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 24 | Sign up | Sign up | Sign up |
About Soligenix
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States.
| Price | $2.79 |
| Target Price | Sign up |
| Volume | 120,780 |
| Market Cap | $13M |
| Year Range | $1.12 - $4.96 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
 |
Soligenix (NASDAQ:SNGX) & Cullinan Therapeutics (NASDAQ:CGEM) Head-To-Head ReviewAugust 25 - ETF Daily News |
Biotech, Pharmaceuticals & Genetics Industry Almanac 2026: Market Research, Statistics, Trends and Leading CompaniesSeptember 11 - GlobeNewswire |
|
Hodgkin’s Lymphoma Market Set to Reach New Heights by 2034 with Innovative Therapies and Clinical Successes | DelveInsightAugust 28 - GlobeNewswire |
|
 |
Promising Defense Stocks To Add to Your Watchlist – August 18thAugust 21 - ETF Daily News |
 |
HDAC Inhibitors Market Sees Upward Trajectory Across the 7MM During the Forecast Period (2025-2034) Driven by Innovation in Cancer Therapies | DelveInsightAugust 20 - PR Newswire UK |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 0 | 0 | 0 | -2.7M | 0 | -0.820 |
| Q1 '25 | 0 | 0 | 0 | -3.2M | -3.3M | -1.060 |
| Q4 '24 | 6,400 | 1,000 | 0 | -3M | -3.7M | -1.140 |
| Q3 '24 | 0 | 0 | 0 | -1.7M | -1.9M | -0.780 |
| Q2 '24 | 2,300 | 2,300 | -1,600 | -1.6M | -1.8M | -1.310 |
Insider Transactions View All
| Straube Richard filed to buy 8,000 shares at $0.5. May 18 '22 |
| SCHABER CHRISTOPHER J filed to buy 90,095 shares at $0.4. May 18 '22 |
Similar companies
Read more about Soligenix (SNGX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Soligenix?
The Market Cap of Soligenix is $13M.
What is the current stock price of Soligenix?
Currently, the price of one share of Soligenix stock is $2.79.
How can I analyze the SNGX stock price chart for investment decisions?
The SNGX stock price chart above provides a comprehensive visual representation of Soligenix's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Soligenix shares. Our platform offers an up-to-date SNGX stock price chart, along with technical data analysis and alternative data insights.
Does SNGX offer dividends to its shareholders?
As of our latest update, Soligenix (SNGX) does not offer dividends to its shareholders. Investors interested in Soligenix should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Soligenix?
Some of the similar stocks of Soligenix are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.